Literature DB >> 16331624

TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.

Keisuke Tateishi1, Miki Ohta, Bayasi Guleng, Fumihiko Kanai, Yasuo Tanaka, Yoshinari Asaoka, Amarsanaa Jazag, Jun Imamura, Takaaki Imamura, Hideaki Ijichi, Tsuneo Ikenoue, Takayuki Kawakami, Yasushi Fukushima, Miwa Washida, Masataka Sata, Makoto Miyagishi, Kazunari Taira, Haruhiko Yoshida, Takao Kawabe, Masao Omata.   

Abstract

The graft-versus-tumor (GVT) effect that occurs following allogeneic bone marrow transplantation (BMT) and donor lymphocyte infusion (DLI) is currently being subjected to intensive investigation because of clinical evidence for GVT efficacy against leukemia. In this report, we investigate the efficacy and molecular mechanisms of GVT against solid tumors, using a modification of the mouse parent-to-F1 BMT model. Mouse Colon26 cells in which tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptor expression was stably knocked down were transplanted to investigate the role of the TRAIL-TRAIL receptor system in the GVT effect. In addition, Fas ligand-(FasL) deficient mice on a C57BL6 (B6) background were used as donors, to determine the significance of the Fas-FasL system for the antitumor effect. The group that received B6 DLI followed by preconditioning with 950 rad irradiation underwent tumor reduction associated with the induction of IFN-gamma, TRAIL and tumor-cell apoptosis. In vitro cultured Colon26 cells were resistant to TRAIL but susceptible to the combination of IFN-gamma and TRAIL in a TRAIL-dose-dependent manner. The infusion of lymphocytes from FasL-defective donors reduced the tumor progression, although efficacy was decreased in the TRAIL receptor knockdown tumors but not in wild-type ones, compared with infusion of B6-derived lymphocytes. The findings indicate that GVT activity against subcutaneous colon tumors is efficiently induced by preconditioning with irradiation and allogeneic DLI, and that TRAIL and IFN-gamma act cooperatively in the antitumor effect. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331624     DOI: 10.1002/ijc.21658

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 2.  Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

Authors:  Anne Grosse-Wilde; Christopher J Kemp
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Concanavalin A/IFN-gamma triggers autophagy-related necrotic hepatocyte death through IRGM1-mediated lysosomal membrane disruption.

Authors:  Chih-Peng Chang; Ming-Chen Yang; Huan-Yao Lei
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

4.  Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.

Authors:  Adel Galal El-Shemi; Ahmad Mohammed Ashshi; Youjin Na; Yan Li; Mohammed Basalamah; Faisal Ahmad Al-Allaf; Eonju Oh; Bo-Kyeong Jung; Chae-Ok Yun
Journal:  J Exp Clin Cancer Res       Date:  2016-05-06

Review 5.  Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Wei Du; Xuefang Cao
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.